83 related articles for article (PubMed ID: 16328415)
1. Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisation.
Delord JP; Léger F; Canal P; Poublanc M; Bugat R; Chatelut E
Cancer Chemother Pharmacol; 2006 Aug; 58(2):189-94. PubMed ID: 16328415
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
3. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
Gerrits CJ; Schellens JH; Burris H; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Von Hoff DD; Verweij J
Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
[TBL] [Abstract][Full Text] [Related]
4. Individual adaptive dosing of topotecan in ovarian cancer.
Montazeri A; Culine S; Laguerre B; Pinguet F; Lokiec F; Albin N; Goupil A; Déporte-Féty R; Bugat R; Canal P; Chatelut E
Clin Cancer Res; 2002 Feb; 8(2):394-9. PubMed ID: 11839654
[TBL] [Abstract][Full Text] [Related]
5. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
[TBL] [Abstract][Full Text] [Related]
6. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
Boss DS; Siegel-Lakhai WS; van Egmond-Schoemaker NE; Pluim D; Rosing H; Ten Bokkel Huinink WW; Beijnen JH; Schellens JH
Clin Cancer Res; 2009 Jul; 15(13):4475-83. PubMed ID: 19531625
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol.
Lotz JP; Pautier P; Selle F; Viens P; Fabbro M; Lokiec F; Viret F; Gligorov J; Gosse B; Provent S; Ribrag V; Micléa JM; Dosquet C; Goetschel A; Cailliot C; Lefèvre G; Genève J; Lhommé C;
Bone Marrow Transplant; 2006 Apr; 37(7):669-75. PubMed ID: 16501591
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.
Daw NC; Santana VM; Iacono LC; Furman WL; Hawkins DR; Houghton PJ; Panetta JC; Gajjar AJ; Stewart CF
J Clin Oncol; 2004 Mar; 22(5):829-37. PubMed ID: 14990638
[TBL] [Abstract][Full Text] [Related]
9. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.
Shibayama T; Hotta K; Takigawa N; Tada A; Ueoka H; Harita S; Kiura K; Tabata M; Segawa Y; Nogami N; Kuyama S; Shinkai T; Tanimoto M
Lung Cancer; 2006 Aug; 53(2):189-95. PubMed ID: 16806573
[TBL] [Abstract][Full Text] [Related]
10. No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.
Zackrisson AL; Malmström H; Peterson C
Eur J Clin Pharmacol; 2002 May; 58(2):103-8. PubMed ID: 12012141
[TBL] [Abstract][Full Text] [Related]
11. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors.
Santana VM; Zamboni WC; Kirstein MN; Tan M; Liu T; Gajjar A; Houghton PJ; Stewart CF
Clin Cancer Res; 2003 Feb; 9(2):633-40. PubMed ID: 12576429
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.
Garcia AA; Roman L; Muderspach L; O'meara A; Facio G; Edwards S; Burnett A
Cancer Invest; 2005; 23(8):665-70. PubMed ID: 16377584
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
[TBL] [Abstract][Full Text] [Related]
14. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach.
Santana VM; Furman WL; Billups CA; Hoffer F; Davidoff AM; Houghton PJ; Stewart CF
J Clin Oncol; 2005 Jun; 23(18):4039-47. PubMed ID: 15961757
[TBL] [Abstract][Full Text] [Related]
15. Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study.
Rose PG; Markman M; Bell JG; Fusco NL
Gynecol Oncol; 2006 Aug; 102(2):236-9. PubMed ID: 16412499
[TBL] [Abstract][Full Text] [Related]
16. Mechanism-based models for topotecan-induced neutropenia.
Léger F; Loos WJ; Bugat R; Mathijssen RH; Goffinet M; Verweij J; Sparreboom A; Chatelut E
Clin Pharmacol Ther; 2004 Dec; 76(6):567-78. PubMed ID: 15592328
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of periocular topotecan in children with intraocular retinoblastoma.
Chantada GL; Fandino AC; Carcaboso AM; Lagomarsino E; de Davila MT; Guitter MR; Rose AB; Manzitti J; Bramuglia GF; Abramson DH
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1492-6. PubMed ID: 18978345
[TBL] [Abstract][Full Text] [Related]
18. Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study.
Metzger ML; Stewart CF; Freeman BB; Billups CA; Hoffer FA; Wu J; Coppes MJ; Grant R; Chintagumpala M; Mullen EA; Alvarado C; Daw NC; Dome JS
J Clin Oncol; 2007 Jul; 25(21):3130-6. PubMed ID: 17634492
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
Mita AC; Denis LJ; Rowinsky EK; Debono JS; Goetz AD; Ochoa L; Forouzesh B; Beeram M; Patnaik A; Molpus K; Semiond D; Besenval M; Tolcher AW
Clin Cancer Res; 2009 Jan; 15(2):723-30. PubMed ID: 19147780
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors.
Mould DR; Holford NH; Schellens JH; Beijnen JH; Hutson PR; Rosing H; ten Bokkel Huinink WW; Rowinsky EK; Schiller JH; Russo M; Ross G
Clin Pharmacol Ther; 2002 May; 71(5):334-48. PubMed ID: 12011819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
